Stroke is the leading cause of human disability with limited effective drugs availability. The disruption of multiple signaling pathways in stroke makes developing new drugs be difficult. Traditional Chinese medicine(...Stroke is the leading cause of human disability with limited effective drugs availability. The disruption of multiple signaling pathways in stroke makes developing new drugs be difficult. Traditional Chinese medicine(TCM) has its unique advantage in targeting multiple signaling pathways with multiple components. Many TCM formulas have the potential for neuroprotection and neurogenesis, but well-designed clinical trials are insufficient and underlying mechanisms unclear. Herein, we introduce the commonly used TCM formulas for stroke treatment and selectively introduce two classic formulas, An Gong Niu Huang(AGNH) pill and Bu Yang Huan Wu Decoction(BYHWD) for neuroprotection and neurogenesis, respectively. Current scientific evidence and clinical trials indicate AGNH pill could be an effective neuroprotective formula as adjunct therapy with relative safety. On the other hand, as a representative TCM formula for post stroke disability, BYHWD could improve the neurological outcome with its neuroprotective and neurogenic effects. The underlying mechanisms could be attributed to the modulation of multiple molecular targets with its multiple components. In conclusion, TCM formulas could be potential adjunct therapies for stroke treatment. The clinical efficacies and molecular mechanisms of promoting neuroprotection and neurogenesis remain to be further studies.展开更多
目的:研究双醋瑞因胶囊联合牛杞地黄丸治疗膝关节骨关节炎(Osteoarthritis,OA)的可行性及安全性。方法:选取100例骨性关节炎病人,治疗组50人,对照组50人,治疗组采用双醋瑞因胶囊联合牛杞地黄丸治疗,对照组服用采用美洛昔康片,治疗前后...目的:研究双醋瑞因胶囊联合牛杞地黄丸治疗膝关节骨关节炎(Osteoarthritis,OA)的可行性及安全性。方法:选取100例骨性关节炎病人,治疗组50人,对照组50人,治疗组采用双醋瑞因胶囊联合牛杞地黄丸治疗,对照组服用采用美洛昔康片,治疗前后采用国际通用的WOMAC VA 3.1疗效评价量表,分别于治疗前、治疗4 w、治疗8 w及治疗结束后12 w随访时进行疗效评价。结果:治疗组治疗后各个时间点WOMAC VA 3.1量表各项得分均显著优于治疗前及对照组(P<0.001)。结论:双醋瑞因联合牛杞地黄丸可以有效治疗膝骨性关节炎。展开更多
基金funding support from the Hong Kong Innovation and Technology Commission ITF grant (UIM/289)Grant from National Natural Science Foundation of China (No. 31570855)Contract Research Project of Beijing Tong Ren Tang Chinese Medicine Co. Ltd.
文摘Stroke is the leading cause of human disability with limited effective drugs availability. The disruption of multiple signaling pathways in stroke makes developing new drugs be difficult. Traditional Chinese medicine(TCM) has its unique advantage in targeting multiple signaling pathways with multiple components. Many TCM formulas have the potential for neuroprotection and neurogenesis, but well-designed clinical trials are insufficient and underlying mechanisms unclear. Herein, we introduce the commonly used TCM formulas for stroke treatment and selectively introduce two classic formulas, An Gong Niu Huang(AGNH) pill and Bu Yang Huan Wu Decoction(BYHWD) for neuroprotection and neurogenesis, respectively. Current scientific evidence and clinical trials indicate AGNH pill could be an effective neuroprotective formula as adjunct therapy with relative safety. On the other hand, as a representative TCM formula for post stroke disability, BYHWD could improve the neurological outcome with its neuroprotective and neurogenic effects. The underlying mechanisms could be attributed to the modulation of multiple molecular targets with its multiple components. In conclusion, TCM formulas could be potential adjunct therapies for stroke treatment. The clinical efficacies and molecular mechanisms of promoting neuroprotection and neurogenesis remain to be further studies.
文摘目的:研究双醋瑞因胶囊联合牛杞地黄丸治疗膝关节骨关节炎(Osteoarthritis,OA)的可行性及安全性。方法:选取100例骨性关节炎病人,治疗组50人,对照组50人,治疗组采用双醋瑞因胶囊联合牛杞地黄丸治疗,对照组服用采用美洛昔康片,治疗前后采用国际通用的WOMAC VA 3.1疗效评价量表,分别于治疗前、治疗4 w、治疗8 w及治疗结束后12 w随访时进行疗效评价。结果:治疗组治疗后各个时间点WOMAC VA 3.1量表各项得分均显著优于治疗前及对照组(P<0.001)。结论:双醋瑞因联合牛杞地黄丸可以有效治疗膝骨性关节炎。
